Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Abbott wins FDA approval for dual-energy ablation catheter

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at medtechdive.com →

◆ Verified

Fusion42 · 8 September 2026 · Fusion42 review

Abbott has received FDA approval for its dual-energy ablation catheter, a device aimed at treating atrial fibrillation. The company expects this, along with its Volt PFA device, to help regain market share in electrophysiology treatments.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

Medtech founders focusing on cardiac ablation must act fast to evaluate Abbott's approved catheter as it reshapes competitive dynamics. Your opportunity is to explore gaps left as Abbott closes in on market lead.

◆ Coverage

3 sources · 8 Sep 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalmedical-deviceatrial-fibrillationablation-catheterelectrophysiology